1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/15/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 86.37% | Stifel | Annabel Samimy | $225 → $230 | Maintains | Buy | Get Alert |
03/14/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 62.06% | HC Wainwright & Co. | Oren Livnat | $204 → $200 | Maintains | Buy | Get Alert |
03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 86.37% | Barclays | Balaji Prasad | $235 → $230 | Maintains | Overweight | Get Alert |
03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 6.15% | UBS | Ashwani Verma | $135 → $131 | Maintains | Neutral | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 45.86% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 58.01% | RBC Capital | Gregory Renza | → $195 | Reiterates | Outperform → Outperform | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 37.75% | JP Morgan | Jessica Fye | $180 → $170 | Maintains | Overweight | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 78.27% | Needham | Ami Fadia | $225 → $220 | Maintains | Buy | Get Alert |
01/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 90.42% | Barclays | Balaji Prasad | $240 → $235 | Maintains | Overweight | Get Alert |
01/03/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 29.65% | Baird | Joel Beatty | → $160 | Initiates | → Outperform | Get Alert |
12/04/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 62.06% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 82.32% | Needham | Ami Fadia | → $225 | Reiterates | Buy → Buy | Get Alert |
11/27/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 9.39% | UBS | Ashwani Verma | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
11/09/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 54.77% | RBC Capital | Gregory Renza | $200 → $191 | Maintains | Outperform | Get Alert |
11/09/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 82.32% | Needham | Ami Fadia | $226 → $225 | Maintains | Buy | Get Alert |
09/29/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | — | Raymond James | Gary Nachman | — | Initiates | → Market Perform | Get Alert |
08/22/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 45.86% | Cantor Fitzgerald | Brandon Folkes | → $180 | Reiterates | Overweight → Overweight | Get Alert |
08/14/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 45.86% | Cantor Fitzgerald | Brandon Folkes | $210 → $180 | Maintains | Overweight | Get Alert |
08/11/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $123.41 | 65.3% | HC Wainwright & Co. | Oren Livnat | → $204 | Reiterates | Buy → Buy | Get Alert |
The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by Stifel on March 15, 2024. The analyst firm set a price target for $230.00 expecting JAZZ to rise to within 12 months (a possible 86.37% upside). 30 analyst firms have reported ratings in the last year.
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ: JAZZ) was provided by Stifel, and Jazz Pharmaceuticals maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $225.00 to $230.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $123.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.